[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

USRE49893E1 · kind E1 · reissue

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Alaric J. Dyckman · Lawrenceville, US
• Dharmpal S. Dodd · Princeton, US
• Tasir Shamsul Hague · Yardley, US
• Louis J. Lombardo · Montgomery, US
• John E. Macor · Guilford, US
• Christopher P. Mussari · Princeton, US
• Laxman Pasunoori · Warangal, IN
• Sreekantha Ratna Kumar · Bengaluru, IN
• Trevor C. Sherwood · Plainsboro, US
• Shoshana L. Posy · Highland Park, US
• Ramesh Kumar Sistla · Bengaluru, IN
• Subramanya Hegde · Kanchinakote, IN
• Anupama Kandhi Ramachandra Reddy · Chitradurga, IN

Key dates

• Filing date: Jan 25, 2022
• Grant date: Apr 2, 2024
• Expiry date: Jan 25, 2042

Classification

• Technology area (CPC —): General

Abstract

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.